Estela Jacinto

Dr. Estela Jacinto

Rutgers University RWJ Medical School
orcid

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 October 2004 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
Estela JacintoEstela Jacinto
Estela Jacinto
RLRobbie Loewith
Robbie Loewith
ASAnja Schmidt
Anja Schmidt
SLShuo Lin
Shuo Lin
MRMarkus A. Rüegg
Markus A. Rüegg
MHMichael N. Hall
Michael N. Hall

1 September 2002 in Molecular Cell
Verified
Journal Article
Closed access
RLRobbie Loewith
Robbie Loewith
Estela JacintoEstela Jacinto
Estela Jacinto
SWStephan Wullschleger
Stephan Wullschleger
ALAnja Lorberg
Anja Lorberg
Jose CrespoJose Crespo
Jose Crespo
MHMichael N. Hall
Michael N. Hall

1 October 2006 in Cell
Verified
Journal Article
Closed access
Estela JacintoEstela Jacinto
Estela Jacinto
VFValeria Facchinetti
Valeria Facchinetti
DLDou Liu
Dou Liu
NSNelyn Soto
Nelyn Soto
SWShiniu Wei
Shiniu Wei
BSBing Su
Bing Su

18 February 2021 in Physiological Reviews
Verified
Journal Article
Closed access
PDF file
ASAngelia Szwed
Angelia Szwed
EKEugene Kim
Eugene Kim
Estela JacintoEstela Jacinto
Estela Jacinto
Cells metabolize nutrients for biosynthetic and bioenergetic needs to fuel growth and proliferation. The uptake of nutrients from the environment and their intracellular metabolism is a highly controlled process that involves cross talk between growth signaling and metabolic pathways. Despite constant fluctuations in nutrient availability and environmental signals, normal cells restore metabolic homeostasis to maintain cellular functions and prevent disease. A central signaling molecule that integrates growth with metabolism is the mechanistic target of rapamycin (mTOR). mTOR is a protein kinase that responds to levels of nutrients and growth signals. mTOR forms two protein complexes, mTORC1, which is sensitive to rapamycin, and mTORC2, which is not directly inhibited by this drug. Rapamycin has facilitated the discovery of the various functions of mTORC1 in metabolism. Genetic models that disrupt either mTORC1 or mTORC2 have expanded our knowledge of their cellular, tissue, as well as systemic functions in metabolism. Nevertheless, our knowledge of the regulation and functions of mTORC2, particularly in metabolism, has lagged behind. Since mTOR is an important target for cancer, aging, and other metabolism-related pathologies, understanding the distinct and overlapping regulation and functions of the two mTOR complexes is vital for the development of more effective therapeutic strategies. This review discusses the key discoveries and recent findings on the regulation and metabolic functions of the mTOR complexes. We highlight findings from cancer models but also discuss other examples of the mTOR-mediated metabolic reprogramming occurring in stem and immune cells, type 2 diabetes/obesity, neurodegenerative disorders, and aging.

1 June 1994 in Cell
Verified
Journal Article
Closed access
BSBing Su
Bing Su
Estela JacintoEstela Jacinto
Estela Jacinto
MHMasahiko Hibi
Masahiko Hibi
Tuula KallunkiTuula Kallunki
Tuula Kallunki
MKMichael Karin
Michael Karin
YBYinon Ben-Neriah
Yinon Ben-Neriah

15 July 2011 in Cell Cycle
Verified
Journal Article
Open access
PDF file
WOWon Jun Oh
Won Jun Oh
Estela JacintoEstela Jacinto
Estela Jacinto
The mechanistic target of rapamycin (mTOR) plays a central role in cellular growth and metabolism. mTOR forms two distinct protein complexes, mTORC1 and mTORC2. Much is known about the regulation and functions of mTORC1 due to availability of a natural compound, rapamycin, that inhibits this complex. Studies that define mTORC2 cellular functions and signaling have lagged behind. The development of pharmacological inhibitors that block mTOR kinase activity, and thereby inhibit both mTOR complexes, along with availability of mice with genetic knockouts in mTOR complex components have now provided new insights on mTORC2 function and regulation. Since prolonged effects of rapamycin can also disrupt mTORC2, it is worth re-evaluating the contribution of this less-studied mTOR complex in cancer, metabolic disorders and aging. In this review, we focus on recent developments on mammalian mTORC2 signaling mechanisms and its cellular and tissue-specific functions.